Clinical Context
A 58-year-old patient with a history of progressive ischemic cardiomyopathy and refractory heart failure receives a subcutaneous injection of A2004 (Xcellistem, 1 mg) as part of a cell-based biologic therapy regimen. The patient presents to an outpatient infusion clinic or ambulatory surgical center for administration. The clinical workflow includes pre-procedure review of indications and allergies, informed consent, baseline vital signs and cardiac monitoring, preparation of the product under aseptic technique by pharmacy or trained staff, verification of product dose and patient identity, administration via subcutaneous or intramuscular injection depending on manufacturer instructions, a 30–60 minute post-injection observation period for immediate adverse reactions, and documentation of lot number, dosage, route, site, and any immediate adverse events in the medical record. Typical sites of service are outpatient infusion centers, ambulatory surgical centers, physician offices with appropriate credentialing, or hospital outpatient departments. Payors commonly involved in coverage decisions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.